| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Trials as Topic | 12 | 2021 | 7913 | 0.650 |
Why?
|
| Glioblastoma | 13 | 2023 | 3481 | 0.550 |
Why?
|
| Brain Neoplasms | 18 | 2023 | 8863 | 0.460 |
Why?
|
| Electronic Health Records | 2 | 2020 | 4468 | 0.450 |
Why?
|
| Camptothecin | 4 | 2003 | 576 | 0.430 |
Why?
|
| Metagenomics | 1 | 2014 | 428 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2020 | 9959 | 0.350 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2010 | 288 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2020 | 11524 | 0.320 |
Why?
|
| Astrocytoma | 4 | 1999 | 790 | 0.320 |
Why?
|
| Neoplasms | 13 | 2023 | 21683 | 0.290 |
Why?
|
| Medical Oncology | 6 | 2023 | 2265 | 0.290 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 1708 | 0.270 |
Why?
|
| Models, Theoretical | 2 | 2017 | 3589 | 0.260 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 5319 | 0.260 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 4803 | 0.250 |
Why?
|
| Sample Size | 2 | 2022 | 845 | 0.240 |
Why?
|
| Statistics as Topic | 2 | 2010 | 2373 | 0.240 |
Why?
|
| Bacteria | 1 | 2014 | 2114 | 0.230 |
Why?
|
| Confidentiality | 1 | 2008 | 612 | 0.230 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 4042 | 0.230 |
Why?
|
| Meningococcal Infections | 1 | 2023 | 77 | 0.220 |
Why?
|
| Meningococcal Vaccines | 1 | 2023 | 95 | 0.220 |
Why?
|
| Biomedical Research | 4 | 2021 | 3309 | 0.220 |
Why?
|
| Computational Biology | 1 | 2014 | 3521 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
| Glioma | 6 | 2023 | 3401 | 0.210 |
Why?
|
| Bone Marrow Transplantation | 14 | 2001 | 2765 | 0.210 |
Why?
|
| Exercise | 1 | 2017 | 5615 | 0.190 |
Why?
|
| Lymphopenia | 1 | 2023 | 285 | 0.190 |
Why?
|
| Research Design | 7 | 2020 | 5987 | 0.190 |
Why?
|
| Cancer Vaccines | 2 | 2023 | 1023 | 0.190 |
Why?
|
| Genomics | 1 | 2016 | 5720 | 0.180 |
Why?
|
| Financing, Organized | 1 | 2021 | 202 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2011 | 9239 | 0.180 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2020 | 138 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 5 | 2011 | 627 | 0.170 |
Why?
|
| Antineoplastic Agents | 9 | 2018 | 13695 | 0.170 |
Why?
|
| Dacarbazine | 3 | 2011 | 566 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2015 | 5221 | 0.160 |
Why?
|
| Cerebral Revascularization | 1 | 2020 | 238 | 0.160 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2009 | 371 | 0.150 |
Why?
|
| Algorithms | 2 | 2017 | 13881 | 0.150 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2014 | 323 | 0.140 |
Why?
|
| Environmental Health | 1 | 1999 | 278 | 0.140 |
Why?
|
| Humans | 99 | 2023 | 744343 | 0.140 |
Why?
|
| Research Personnel | 1 | 2021 | 573 | 0.140 |
Why?
|
| Multiple System Atrophy | 1 | 2017 | 121 | 0.140 |
Why?
|
| Spouses | 1 | 1999 | 286 | 0.140 |
Why?
|
| Supratentorial Neoplasms | 1 | 1997 | 160 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 5 | 2020 | 892 | 0.140 |
Why?
|
| Anticonvulsants | 3 | 2011 | 1916 | 0.130 |
Why?
|
| Stem Cell Research | 1 | 2016 | 56 | 0.130 |
Why?
|
| Baltimore | 4 | 2010 | 231 | 0.130 |
Why?
|
| Health Status Indicators | 1 | 2020 | 969 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2003 | 624 | 0.120 |
Why?
|
| Carmustine | 4 | 2003 | 137 | 0.120 |
Why?
|
| Pleural Effusion, Malignant | 2 | 1994 | 101 | 0.120 |
Why?
|
| Cranial Irradiation | 3 | 2010 | 401 | 0.120 |
Why?
|
| Sulfonamides | 3 | 2009 | 1938 | 0.120 |
Why?
|
| Societies, Medical | 3 | 2023 | 3743 | 0.120 |
Why?
|
| Adenocarcinoma | 7 | 2020 | 6364 | 0.120 |
Why?
|
| Lung Neoplasms | 9 | 2015 | 13102 | 0.120 |
Why?
|
| Family Health | 1 | 1999 | 1282 | 0.120 |
Why?
|
| Radiotherapy | 2 | 2019 | 1533 | 0.110 |
Why?
|
| Epistasis, Genetic | 1 | 2016 | 365 | 0.110 |
Why?
|
| Pyrazoles | 3 | 2009 | 1972 | 0.110 |
Why?
|
| Nontherapeutic Human Experimentation | 1 | 2012 | 24 | 0.110 |
Why?
|
| Drug Evaluation | 4 | 2005 | 647 | 0.110 |
Why?
|
| Data Collection | 2 | 2020 | 3341 | 0.110 |
Why?
|
| Sialoglycoproteins | 1 | 2013 | 318 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 3 | 2013 | 1376 | 0.110 |
Why?
|
| Immunotherapy | 4 | 2023 | 4445 | 0.110 |
Why?
|
| Graft vs Host Disease | 8 | 2007 | 2957 | 0.100 |
Why?
|
| Pain Measurement | 2 | 1992 | 3420 | 0.100 |
Why?
|
| Middle Aged | 50 | 2023 | 213383 | 0.100 |
Why?
|
| Tetracyclines | 1 | 2011 | 60 | 0.100 |
Why?
|
| Combined Modality Therapy | 13 | 2019 | 8642 | 0.090 |
Why?
|
| Delaware | 1 | 2010 | 16 | 0.090 |
Why?
|
| West Virginia | 1 | 2010 | 28 | 0.090 |
Why?
|
| Antineoplastic Protocols | 1 | 2010 | 50 | 0.090 |
Why?
|
| Virginia | 1 | 2010 | 121 | 0.090 |
Why?
|
| Informed Consent | 3 | 2016 | 995 | 0.090 |
Why?
|
| Placebos | 2 | 2012 | 1676 | 0.090 |
Why?
|
| Paclitaxel | 1 | 1997 | 1708 | 0.090 |
Why?
|
| Aged | 36 | 2020 | 163280 | 0.090 |
Why?
|
| New Jersey | 1 | 2010 | 290 | 0.090 |
Why?
|
| Maryland | 1 | 2010 | 276 | 0.090 |
Why?
|
| Haplotypes | 1 | 2016 | 2779 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2022 | 7729 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2014 | 1959 | 0.080 |
Why?
|
| Pennsylvania | 1 | 2010 | 613 | 0.080 |
Why?
|
| Survival Analysis | 11 | 2013 | 10252 | 0.080 |
Why?
|
| Adult | 45 | 2020 | 214055 | 0.080 |
Why?
|
| Pentostatin | 1 | 2007 | 26 | 0.080 |
Why?
|
| Ecology | 1 | 1988 | 106 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2015 | 1058 | 0.070 |
Why?
|
| New York | 1 | 2010 | 886 | 0.070 |
Why?
|
| Prognosis | 19 | 2020 | 29063 | 0.070 |
Why?
|
| Cancer Care Facilities | 1 | 2010 | 402 | 0.070 |
Why?
|
| Naproxen | 1 | 2007 | 99 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2000 | 523 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2020 | 841 | 0.070 |
Why?
|
| Treatment Outcome | 17 | 2020 | 63114 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 1671 | 0.070 |
Why?
|
| Heart Rate | 1 | 2017 | 4091 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2017 | 2899 | 0.070 |
Why?
|
| Pain | 2 | 1992 | 4986 | 0.070 |
Why?
|
| Male | 44 | 2023 | 350118 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 903 | 0.070 |
Why?
|
| Bayes Theorem | 1 | 2014 | 2309 | 0.070 |
Why?
|
| Cisplatin | 5 | 1999 | 1662 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 5256 | 0.070 |
Why?
|
| Drug Interactions | 3 | 1998 | 1460 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2009 | 1770 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2014 | 6459 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2016 | 3494 | 0.070 |
Why?
|
| Female | 44 | 2023 | 380194 | 0.070 |
Why?
|
| Neoplasm Staging | 9 | 2019 | 11031 | 0.060 |
Why?
|
| Drug Administration Schedule | 5 | 2009 | 4933 | 0.060 |
Why?
|
| Harderian Gland | 1 | 2004 | 3 | 0.060 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2005 | 111 | 0.060 |
Why?
|
| Models, Statistical | 4 | 2005 | 5102 | 0.060 |
Why?
|
| Ampulla of Vater | 1 | 2005 | 141 | 0.060 |
Why?
|
| Patient Selection | 4 | 2015 | 4215 | 0.060 |
Why?
|
| Cyclophosphamide | 9 | 2009 | 2242 | 0.060 |
Why?
|
| Entropy | 1 | 2005 | 209 | 0.060 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2004 | 25 | 0.060 |
Why?
|
| Patient Advocacy | 2 | 2017 | 353 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 3479 | 0.060 |
Why?
|
| Karnofsky Performance Status | 3 | 2011 | 173 | 0.060 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2005 | 236 | 0.060 |
Why?
|
| United States | 9 | 2023 | 69872 | 0.060 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2004 | 137 | 0.060 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2005 | 178 | 0.060 |
Why?
|
| Neurodegenerative Diseases | 1 | 2012 | 1061 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 1988 | 1364 | 0.050 |
Why?
|
| Stem Cells | 1 | 2016 | 3567 | 0.050 |
Why?
|
| Barrett Esophagus | 1 | 2007 | 494 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 1997 | 2274 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2010 | 2453 | 0.050 |
Why?
|
| Safety Management | 1 | 2008 | 783 | 0.050 |
Why?
|
| Information Dissemination | 2 | 2008 | 1099 | 0.050 |
Why?
|
| Suramin | 1 | 2001 | 34 | 0.050 |
Why?
|
| Sleep | 1 | 2017 | 4623 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2023 | 333 | 0.050 |
Why?
|
| Urban Population | 1 | 2010 | 2021 | 0.050 |
Why?
|
| Treatment Failure | 3 | 2007 | 2618 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 3 | 2023 | 9274 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2012 | 2002 | 0.050 |
Why?
|
| Emphysema | 1 | 2004 | 247 | 0.050 |
Why?
|
| Prostate | 1 | 2009 | 1774 | 0.050 |
Why?
|
| Stroke | 2 | 2020 | 9981 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2009 | 1270 | 0.050 |
Why?
|
| Prostatectomy | 3 | 2003 | 1890 | 0.050 |
Why?
|
| Software | 1 | 2014 | 4443 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2004 | 547 | 0.050 |
Why?
|
| Leukemia | 2 | 2007 | 1511 | 0.050 |
Why?
|
| Hodgkin Disease | 3 | 2001 | 1415 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 975 | 0.040 |
Why?
|
| Uncertainty | 1 | 2005 | 734 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 10943 | 0.040 |
Why?
|
| Transplantation, Autologous | 8 | 2001 | 2124 | 0.040 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2019 | 25 | 0.040 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2000 | 246 | 0.040 |
Why?
|
| Actuarial Analysis | 6 | 2001 | 378 | 0.040 |
Why?
|
| Antisickling Agents | 1 | 1999 | 80 | 0.040 |
Why?
|
| Mastectomy | 1 | 2007 | 1793 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 1992 | 1519 | 0.040 |
Why?
|
| Transplantation | 1 | 2000 | 217 | 0.040 |
Why?
|
| Radiometry | 1 | 2004 | 800 | 0.040 |
Why?
|
| Propionates | 1 | 1999 | 169 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 1677 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 1855 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 802 | 0.040 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1999 | 316 | 0.040 |
Why?
|
| Prostatic Neoplasms | 4 | 2009 | 11124 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2000 | 623 | 0.040 |
Why?
|
| Nevada | 1 | 2017 | 22 | 0.040 |
Why?
|
| Models, Animal | 1 | 2005 | 2171 | 0.040 |
Why?
|
| Retreatment | 1 | 2000 | 610 | 0.040 |
Why?
|
| Receptors, AMPA | 2 | 2010 | 331 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 2000 | 452 | 0.040 |
Why?
|
| Viremia | 1 | 2000 | 736 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8428 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2000 | 648 | 0.040 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 57776 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2023 | 1470 | 0.040 |
Why?
|
| Mortality | 1 | 1988 | 2864 | 0.040 |
Why?
|
| Sputum | 1 | 1999 | 476 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2019 | 539 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2019 | 339 | 0.040 |
Why?
|
| Adolescent | 15 | 2010 | 85781 | 0.040 |
Why?
|
| Phenotype | 1 | 2014 | 16365 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2007 | 1583 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2019 | 440 | 0.040 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 39050 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 1993 | 7279 | 0.030 |
Why?
|
| Remission Induction | 4 | 2005 | 2386 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 19905 | 0.030 |
Why?
|
| Survival Rate | 6 | 2010 | 12788 | 0.030 |
Why?
|
| Outpatients | 1 | 2023 | 1486 | 0.030 |
Why?
|
| Fluorouracil | 3 | 1991 | 1619 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2005 | 2421 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2005 | 2072 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 2000 | 1092 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 684 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 220 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2001 | 1301 | 0.030 |
Why?
|
| Registries | 2 | 2022 | 8089 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 2 | 2003 | 2494 | 0.030 |
Why?
|
| Disease-Free Survival | 5 | 2007 | 6895 | 0.030 |
Why?
|
| Consent Forms | 1 | 1994 | 53 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2019 | 826 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 2716 | 0.030 |
Why?
|
| Random Allocation | 2 | 1992 | 2429 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2000 | 570 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2000 | 1381 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 1999 | 986 | 0.030 |
Why?
|
| Specimen Handling | 1 | 1999 | 694 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 4149 | 0.030 |
Why?
|
| Whole-Body Irradiation | 2 | 1992 | 449 | 0.030 |
Why?
|
| Transplantation, Homologous | 4 | 2001 | 4776 | 0.030 |
Why?
|
| Gastrectomy | 1 | 2019 | 663 | 0.030 |
Why?
|
| Child | 15 | 2010 | 77709 | 0.030 |
Why?
|
| Time Factors | 6 | 2011 | 40075 | 0.030 |
Why?
|
| Benzodiazepines | 2 | 2010 | 1101 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2019 | 850 | 0.030 |
Why?
|
| Recurrence | 6 | 2007 | 8340 | 0.030 |
Why?
|
| Bone Marrow | 3 | 2005 | 2948 | 0.030 |
Why?
|
| Incidence | 3 | 2019 | 20947 | 0.030 |
Why?
|
| Cytarabine | 2 | 1994 | 692 | 0.030 |
Why?
|
| Breast Neoplasms | 3 | 2009 | 20822 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 1738 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2022 | 2258 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2001 | 895 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 1997 | 973 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2003 | 15540 | 0.030 |
Why?
|
| Drug Resistance | 3 | 2007 | 1609 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 5137 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2023 | 2725 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 4851 | 0.030 |
Why?
|
| Ethics | 1 | 1992 | 94 | 0.030 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 1992 | 38 | 0.030 |
Why?
|
| Busulfan | 2 | 1992 | 263 | 0.030 |
Why?
|
| Bone Marrow Purging | 1 | 1991 | 109 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2021 | 1580 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2013 | 284 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2013 | 351 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 1206 | 0.020 |
Why?
|
| Writing | 1 | 1993 | 206 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 1991 | 3523 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3586 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2005 | 6196 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2023 | 53288 | 0.020 |
Why?
|
| Interferon Inducers | 1 | 2010 | 25 | 0.020 |
Why?
|
| Reading | 1 | 1994 | 558 | 0.020 |
Why?
|
| Snake Venoms | 1 | 2010 | 39 | 0.020 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2010 | 39 | 0.020 |
Why?
|
| gamma-Globulins | 1 | 1990 | 124 | 0.020 |
Why?
|
| Animals | 3 | 2016 | 168757 | 0.020 |
Why?
|
| Hospitals, University | 1 | 1992 | 571 | 0.020 |
Why?
|
| Poly I-C | 1 | 2010 | 115 | 0.020 |
Why?
|
| Growth | 1 | 1992 | 376 | 0.020 |
Why?
|
| Polylysine | 1 | 2010 | 133 | 0.020 |
Why?
|
| Proportional Hazards Models | 6 | 2009 | 12354 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1992 | 1681 | 0.020 |
Why?
|
| Retrospective Studies | 9 | 2023 | 77449 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6538 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2000 | 1596 | 0.020 |
Why?
|
| Comprehension | 1 | 1994 | 610 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1915 | 0.020 |
Why?
|
| Models, Biological | 1 | 1985 | 9583 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 1655 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2009 | 206 | 0.020 |
Why?
|
| Neuroendocrine Tumors | 1 | 1994 | 594 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2009 | 221 | 0.020 |
Why?
|
| Hydrazines | 1 | 1990 | 226 | 0.020 |
Why?
|
| Erythropoietin | 1 | 1992 | 726 | 0.020 |
Why?
|
| Anemia | 2 | 1999 | 1506 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2005 | 7880 | 0.020 |
Why?
|
| Child, Preschool | 10 | 2007 | 41006 | 0.020 |
Why?
|
| Mutation | 2 | 2019 | 29786 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 1991 | 346 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 349 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 2000 | 1965 | 0.020 |
Why?
|
| Mathematics | 1 | 1988 | 728 | 0.020 |
Why?
|
| Thrombocytopenia | 2 | 1999 | 1179 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 629 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2007 | 104 | 0.020 |
Why?
|
| Herpes Zoster | 1 | 1989 | 264 | 0.020 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2009 | 449 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2011 | 2327 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 1991 | 603 | 0.020 |
Why?
|
| Doxorubicin | 2 | 2009 | 2234 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 2007 | 8037 | 0.020 |
Why?
|
| Nootropic Agents | 1 | 2007 | 160 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2000 | 3265 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 4751 | 0.020 |
Why?
|
| HLA Antigens | 2 | 2007 | 1381 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2023 | 25625 | 0.020 |
Why?
|
| Selection Bias | 1 | 2007 | 371 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2011 | 2559 | 0.020 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2005 | 94 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1992 | 1547 | 0.020 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2005 | 130 | 0.020 |
Why?
|
| Lymphoma | 2 | 1991 | 1877 | 0.020 |
Why?
|
| Infant | 6 | 1999 | 35136 | 0.020 |
Why?
|
| Mesothelioma | 1 | 1991 | 818 | 0.020 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2005 | 232 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2007 | 611 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 1903 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2009 | 4286 | 0.010 |
Why?
|
| Clinical Protocols | 2 | 2004 | 1462 | 0.010 |
Why?
|
| Ions | 1 | 2004 | 265 | 0.010 |
Why?
|
| Linear Energy Transfer | 1 | 2004 | 154 | 0.010 |
Why?
|
| Family | 1 | 1994 | 3147 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 1990 | 2715 | 0.010 |
Why?
|
| Decision Making, Organizational | 1 | 2004 | 139 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 1405 | 0.010 |
Why?
|
| Anthracyclines | 1 | 2005 | 288 | 0.010 |
Why?
|
| Age Factors | 3 | 1996 | 18370 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2013 | 5974 | 0.010 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 6489 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 163 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 876 | 0.010 |
Why?
|
| Psychometrics | 1 | 1992 | 3002 | 0.010 |
Why?
|
| Pedigree | 1 | 1990 | 4644 | 0.010 |
Why?
|
| Postoperative Complications | 4 | 2000 | 15295 | 0.010 |
Why?
|
| Stomatitis | 1 | 2005 | 269 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2015 | 3444 | 0.010 |
Why?
|
| Cadherins | 1 | 2007 | 907 | 0.010 |
Why?
|
| Biometry | 1 | 1985 | 558 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 1991 | 1076 | 0.010 |
Why?
|
| Tretinoin | 1 | 2005 | 517 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1991 | 2250 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2009 | 3913 | 0.010 |
Why?
|
| Analysis of Variance | 3 | 2000 | 6365 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 1261 | 0.010 |
Why?
|
| Transfection | 1 | 2009 | 5892 | 0.010 |
Why?
|
| Mass Media | 1 | 2004 | 305 | 0.010 |
Why?
|
| Absorbable Implants | 1 | 2003 | 342 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 4462 | 0.010 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 12245 | 0.010 |
Why?
|
| Filgrastim | 1 | 2000 | 133 | 0.010 |
Why?
|
| Photons | 1 | 2004 | 588 | 0.010 |
Why?
|
| Hemoglobins | 2 | 1999 | 1534 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 780 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2000 | 236 | 0.010 |
Why?
|
| Chronic Disease | 3 | 2003 | 9146 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2009 | 2416 | 0.010 |
Why?
|
| Carcinoma | 1 | 1991 | 2375 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2003 | 1654 | 0.010 |
Why?
|
| Bacterial Toxins | 1 | 2005 | 931 | 0.010 |
Why?
|
| Risk Factors | 8 | 2004 | 72290 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 2849 | 0.010 |
Why?
|
| Protons | 1 | 2004 | 1127 | 0.010 |
Why?
|
| Vidarabine | 1 | 2000 | 345 | 0.010 |
Why?
|
| Virus Activation | 1 | 2000 | 319 | 0.010 |
Why?
|
| Leukopenia | 1 | 1999 | 212 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2000 | 442 | 0.010 |
Why?
|
| Brain Edema | 1 | 2003 | 617 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 2728 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1991 | 4034 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10481 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2000 | 693 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 2282 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2005 | 2513 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 16689 | 0.010 |
Why?
|
| Genome, Viral | 1 | 2000 | 667 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 2000 | 646 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 1991 | 3843 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 4386 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2013 | 11483 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2001 | 2008 | 0.010 |
Why?
|
| Polymers | 1 | 2003 | 1621 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2001 | 719 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2000 | 1041 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2009 | 12026 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2009 | 23338 | 0.010 |
Why?
|
| Gastrin-Releasing Peptide | 1 | 1994 | 38 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2005 | 1352 | 0.010 |
Why?
|
| Disease Progression | 2 | 2003 | 13284 | 0.010 |
Why?
|
| Cell Line | 1 | 2009 | 15997 | 0.010 |
Why?
|
| Chromogranin A | 1 | 1994 | 54 | 0.010 |
Why?
|
| Pleurodesis | 1 | 1994 | 41 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1994 | 135 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2003 | 1736 | 0.010 |
Why?
|
| Skin Diseases | 1 | 2003 | 1065 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 1999 | 885 | 0.010 |
Why?
|
| Ischemic Attack, Transient | 1 | 2000 | 935 | 0.010 |
Why?
|
| Chromogranins | 1 | 1994 | 160 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2000 | 2225 | 0.010 |
Why?
|
| Vimentin | 1 | 1994 | 261 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 1994 | 276 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1999 | 2029 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2000 | 1133 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1994 | 349 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 8301 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2001 | 5442 | 0.010 |
Why?
|
| Carotid Stenosis | 1 | 2000 | 854 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 8324 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 9687 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1991 | 118 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 13033 | 0.010 |
Why?
|
| Viral Load | 1 | 2000 | 3299 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1994 | 927 | 0.010 |
Why?
|
| Hospitalization | 1 | 2011 | 10262 | 0.010 |
Why?
|
| Somatomedins | 1 | 1992 | 192 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1999 | 2617 | 0.010 |
Why?
|
| Bilirubin | 1 | 1992 | 425 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1999 | 1928 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2000 | 6622 | 0.010 |
Why?
|
| Seizures | 1 | 2003 | 2859 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1991 | 387 | 0.010 |
Why?
|
| Philadelphia Chromosome | 1 | 1990 | 112 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2003 | 2214 | 0.010 |
Why?
|
| Glucagon | 1 | 1992 | 533 | 0.010 |
Why?
|
| Vincristine | 1 | 1991 | 1039 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 1990 | 182 | 0.010 |
Why?
|
| Freezing | 1 | 1990 | 303 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1992 | 786 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1992 | 705 | 0.010 |
Why?
|
| Skin Diseases, Infectious | 1 | 1989 | 74 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1989 | 356 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 19229 | 0.010 |
Why?
|
| Premedication | 1 | 1989 | 258 | 0.010 |
Why?
|
| Herpesvirus 3, Human | 1 | 1989 | 204 | 0.000 |
Why?
|
| Azathioprine | 1 | 1989 | 353 | 0.000 |
Why?
|
| Blood Chemical Analysis | 1 | 1990 | 440 | 0.000 |
Why?
|
| Rats | 1 | 2004 | 24260 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1990 | 1420 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1990 | 20129 | 0.000 |
Why?
|
| Platelet Count | 1 | 1990 | 781 | 0.000 |
Why?
|
| Cohort Studies | 2 | 2003 | 40561 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1990 | 1588 | 0.000 |
Why?
|
| Gene Rearrangement | 1 | 1991 | 1179 | 0.000 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 13989 | 0.000 |
Why?
|
| Body Height | 1 | 1992 | 1577 | 0.000 |
Why?
|
| Prednisone | 1 | 1989 | 1574 | 0.000 |
Why?
|
| Probability | 1 | 1990 | 2505 | 0.000 |
Why?
|
| Methotrexate | 1 | 1990 | 1727 | 0.000 |
Why?
|
| Young Adult | 1 | 2010 | 56430 | 0.000 |
Why?
|
| Chi-Square Distribution | 1 | 1990 | 3508 | 0.000 |
Why?
|
| Peptides | 1 | 1994 | 4409 | 0.000 |
Why?
|
| Feasibility Studies | 1 | 1991 | 5078 | 0.000 |
Why?
|
| Attitude to Health | 1 | 1990 | 2052 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1994 | 11366 | 0.000 |
Why?
|
| Lymphatic Metastasis | 1 | 1988 | 2924 | 0.000 |
Why?
|
| Brain | 1 | 2007 | 26385 | 0.000 |
Why?
|
| Patient Education as Topic | 1 | 1990 | 2278 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1990 | 4199 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 1995 | 15076 | 0.000 |
Why?
|
| Graft Survival | 1 | 1989 | 3737 | 0.000 |
Why?
|
| Acute Disease | 1 | 1989 | 7149 | 0.000 |
Why?
|
| Physician-Patient Relations | 1 | 1990 | 3229 | 0.000 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1989 | 3386 | 0.000 |
Why?
|
| Palliative Care | 1 | 1990 | 3493 | 0.000 |
Why?
|